Phone: 1-415-349-0054 Toll Free: 1-888-202-9519 Email: sales @ radiantinsights. com Web: http:// www. radiantinsights. com /
Frontier Pharma-Hepatitis C Market Research Report 2025
Hepatitis C is a blood-borne viral infection characterized by chronic inflammation of the liver. Although patients may be asymptomatic for a number of years or decades, chronic HCV infection can lead to liver fibrosis( formation of scar tissue) and ultimately liver cirrhosis, in which permanent fibrotic scar tissue replaces healthy liver cells. In severe cases, cirrhosis may lead to liver failure and death. In addition, hepatitis C patients are at an increased risk of developing liver cancer.
Hepatitis C has a high global prevalence, with the number of people living with the disease estimated at 130-170 million worldwide. Before the arrival of direct-acting antivirals( DAA) in 2011, the gold-standard of hepatitis C therapy consisted of the host-targeting drugs pegylated interferonα and ribavirin, which were associated with significant side effects.
Browse Full Research Report @: http:// www. radiantinsights. com / research / frontier-pharmahepatitis-c
Despite the entry of these new therapies, there is a subgroup of patients that do not respond to current treatments, or relapse. In addition, HCV resistance to DAAs may also be a cause for concern, as the development of selection pressure by the host immune system in combination with DAA therapy may lead to outgrowth of resistant viruses. As such, the rationale for investment in first-in-class innovation remains strong.
Reason to Buy:
� Appreciate the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, co-morbidities and complications, and treatment options and algorithms.
� Visualize the composition of the hepatitis C market in terms of dominant classes of therapies. Key unmet needs are identified to allow a competitive understanding of gaps in the market.
� Recognize innovative pipeline trends by analysing therapies by stage of development, molecule type and molecular target.
� Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix tailored to hepatitis C, all first-in-class targets in the hepatitis C pipeline have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.
� Consider first-in-class pipeline products with no prior involvement in licensing and codevelopment deals that may represent potential investment opportunities.
https
:// www. facebook. com / RadiantInsights
https:// www. linkedin. com / company / radiant-insights https:// twitter. com / radiantinsights
https:// plus. google. com /+ Radiantinsights